Not developing potency assays and gaining knowledge about MOAs early in the drug development process not only can break ATMP ...
they found that it indeed killed the cancer cells with high potency. They also tested the molecule in healthy mice and found no obvious toxic side effects, even though the molecule killed off a ...
News Medical on MSN13d
Stanford team uses natural cell death mechanism to kill cancer cellsOur bodies divest themselves of 60 billion cells every day through a natural process of cell culling and turnover called apoptosis.
An emerging class of anticancer drugs called EZH2 inhibitors may greatly enhance the potency of some cancer immunotherapies.
An emerging class of anticancer drugs called EZH2 inhibitors may greatly enhance the potency of some cancer immunotherapies, ...
In the ever-evolving cell therapy landscape, the challenge of potency assay development remains critical. At the 4th Cell Therapy Potency Assay Summit, we will unite analytical development ...
A study in mice offers evidence that inhibiting EZH2 can enhance lymphoma immunogenicity and overcome CAR-T cell therapy resistance.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback